# CAVHANZA
> **NDA217379** · New Drug Application · Sponsor: CYCLE · Approved 2026-05-29
## Drug
- **FDA Application Number:** NDA217379
- **Application type:** New Drug Application
- **Brand name:** CAVHANZA
- **Generic name:** NILOTINIB
- **Active ingredients:** NILOTINIB
- **Dosage form:** TABLET, ORALLY DISINTEGRATING
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** CYCLE
- **Manufacturer:** Cycle Pharmaceuticals Ltd
- **First approval:** 2026-05-29
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217379)
---
*MORVS · CC0 1.0*